

Short Report

Open Access

Stability of methylnicotinate in aqueous solution as utilized in the 'niacin patch test'

Brian M Ross*¹ and Martin Katzman^{1,2}

Address: ¹Northern Ontario School of Medicine, Lakehead University, Thunder Bay, Ontario, Canada and ²The START Mood and Anxiety Disorders Clinic, Toronto, Ontario, Canada

Email: Brian M Ross* - brian.ross@normed.ca; Martin Katzman - mkatzman@startclinic.ca

* Corresponding author

Published: 24 September 2008

Received: 9 April 2008

BMC Research Notes 2008, 1:89 doi:10.1186/1756-0500-1-89

Accepted: 24 September 2008

This article is available from: <http://www.biomedcentral.com/1756-0500/1/89>

© 2008 Ross and Katzman; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The topical application of methylnicotinate results in a localized vasodilatory response which has been found to differ from that observed to occur in healthy controls in a variety of medical conditions. The stability of the drug in aqueous solution is unclear while difficulties can be encountered when preparing methylnicotinate solutions for this purpose. To aid in the determination of how long solutions of the drug should be stored before discarding we have used a collection of aged batches of methylnicotinate to determine the stability of the drug in aqueous solution.

Findings: The degradation of methylnicotinate was determined in batches which had been stored at 4°C for between 5 and 1062 days prior to analysis by High Performance Liquid Chromatography. The major degradation product of methylnicotinate was nicotinic acid which formed at an approximate rate of 0.5% of the starting methylnicotinate concentration per annum. Furthermore, the ability of methylnicotinate solutions of different ages to induce vasodilatation was assessed in healthy volunteers. No significant difference in vasodilatory response was apparent between batches which had been stored for between zero and 1057 days.

Conclusion: Methylnicotinate exhibits excellent chemical and biological stability in solution facilitating its use in clinical applications.

Background

Systemic administration of the B vitamin niacin (nicotinic acid) produces a generalized vasodilatory response [1]. This occurs due to nicotinic acid stimulating the production of prostaglandin D₂ from arachidonic acid in the skin which subsequently acts upon capillary endothelial cells to cause vasodilatation [1,2]. The methylester of nicotinate, methylnicotinate, has a similar vasodilatory effect, however the ester can be applied transcutaneously resulting in a localized, rather than generalized, response [3]. Methylnicotinate has found application as a rubefacient

[4] and in the development and testing of anti-inflammatory drugs [5]. Topical application of methylnicotinate has also been used to investigate the inflammatory response in a variety of disorders including autism [6], Huntington's disease [7], social phobia [8], major depressive disorder [9,10] and schizophrenia [3,10-18]. In this latter application varying doses of methylnicotinate are applied to the skin (normally the forearm) in the form of a patch (frequently, if inaccurately, referred to as a 'niacin patch'). The resulting vasodilatory response is then measured either by the visual estimation of erythema

[4,9] or measuring superficial blood flow by laser Doppler spectrometry [8,13,14]. Such studies have been complicated by the fact that the stability of methylnicotinate in aqueous solution is unknown, necessitating the preparation of new solutions on a regular basis. Besides introducing an additional source of error, the production of new batches of the drug is made difficult due to the high degree of hygroscopicity of solid methylnicotinate. This results in storage and handling difficulties and an inevitable need to regularly discard batches of the solid ester. It would therefore be beneficial to store the aqueous solution for extended periods of time. The stability of methylnicotinate in aqueous solution is not known however, and hence it is unclear for how long the solutions can be stored for. As such many batches of the aqueous drug have been prepared and stored over several years. This has allowed us to investigate the stability of methylnicotinate in solution as well as testing the effect of storage time on the ability of aged preparations to induce erythema, as an aid to determining the storage life of the solution.

Analysis of methylnicotinate degradation in aqueous solution

Methylnicotinate (NHS Highland Labs, UK) was prepared at a concentration of 1 M in water and stored at 4°C in glass containers for between 5 – 1062 days prior to analysis. All batches were prepared using an identical protocol in the same laboratory. No differences in colour or clarity were discernable by visual inspections between batches of different ages, and no batches contained any visible precipitate. The chemical stability of methylnicotinate was investigated using High Performance Liquid Chromatography (HPLC). To accomplish this 1 M stock solutions of methylnicotinate were diluted and methylnicotinate and a degradation product, nicotinic acid, determined in quadruplicate by HPLC using the following analysis parameters: injection volume: 20 µL; separator column: Supelco (Sigma, UK) supelcosil TM LC-18 ODS-18, (length: 25 cm, internal diameter: 4.6 mm, particule size: 5 µm); eluant: 25% v/v methanol in water; eluant flow rate: 1.5 mL/min. Eluted compounds were detected by UV @ 263 nm using an Applied Biosystems Spectroflow 757 UV-vis detector and quantified by comparison with nicotinic acid and 6-methylnicotinate standards (Aldrich, UK). Nicotinic acid had a retention time of 1.4 minutes and a limit of detection of 0.04 µg/ml, while methylnicotinate exhibited a retention time of 7.3 minutes and a limit of detection of 0.05 µg/ml. Within-day variance expressed as the standard deviation as a percentage of the mean was 0.8%, and between day variance was 1.5%. The detection of both nicotine and methylnicotinate showed a linear response with respect to concentration (Pearson correlation coefficient of detector response vs. applied quantity was 0.98) over the range tested using

freshly prepared standards (maximum concentration tested was 150 µg/ml).

The concentration of methylnicotinate in each batch did not differ significantly between batches of different ages, all having the expected measured concentration of approximately 1 M (Figure 1), and there was no significant linear relationship with batch age (Pearson correlation coefficient was 0.001; $P > 0.05$). Qualitative assessment of the chromatograms of freshly prepared methylnicotinate indicated that apart from the compound itself, the predominant contaminant co-eluted with nicotinic acid. Representative chromatograms are shown in Figure 2. The concentration of nicotinic acid in a batch of methylnicotinate prepared 5 days previously was $0.060 \pm 0.002\%$ (mean \pm SD nicotine as a percentage of methylnicotinate analysed in quadruplicate). As illustrated in Figure 1 the degradation of methylnicotinate to form nicotinic acid proceeded linearly with respect to time (Pearson correlation coefficient = 0.98) at a rate of 0.00150% per day (95% confidence interval was 0.001270% to 0.00172%) or 0.54% per 365 day year (95% confidence interval was 0.47% to 0.63%).

Erythema response

In addition to the HPLC analysis, the vasodilatory activity of aged solutions was also investigated. The four batches utilised had been stored for 0, 320, 725 and 1057 days respectively at the time of testing. The 1 M stock solutions were diluted to 10 mM and 1 cm² paper patches were impregnated with approximately 30 µl of the solution as previously described in detail [4]. The patches were applied to the forearms of eight healthy volunteers (4 male, 4 female, age was 44 ± 12 years [mean \pm SD]). The area of skin to which the patch was applied was examined for, and was free of, damage. The skin patch procedure had been reviewed and approved by NHS Highlands Research Ethics Committee. All subjects gave informed consent including that the data obtained from their participation may be published in aggregate format. Erythema, monitored at 5, 10 and 15 minutes after application, was assessed visually using a 4 point scale (0 – no erythema, 1 – perceptible but slight erythema, 2 – moderate erythema, 3 – pronounced erythema). As illustrated in Figure 3, the batch age had no effect upon the extent of erythema (2-way ANOVA with factors time and batch age). There was no statistically significant interaction between time and batch age ($F_{6,56} = 0.21$; $P > 0.9$) nor was there a significant effect of batch age ($F_{3,56} = 0.16$; $P > 0.9$), although there was a statistically significant effect of time ($F_{2,56} = 175.34$; $P < 0.0001$). The testing of the ability of each batch of methylnicotinate to induce erythema was performed using a single dose. We cannot rule out that an effect of batch age would have been observed using different, especially lower, concentrations, although we consider such a




Figure 1
Relationship between batch age, methylnicotinate concentration and relative nicotinic acid content of 1 M aqueous solutions of methylnicotinate. Batches of 1 M methylnicotinate were stored at 4°C for increasing lengths of time prior to analysis by HPLC. Filled circles, plotted on the right axis, show the measured concentration of methylnicotinate in each batch. Open circles, plotted on the left axis, show the percentage of nicotinic acid relative to the total methylnicotinate plus nicotinic acid concentration in each batch. Values shown are the mean of quadruplicate determinations; bars indicate the standard deviation. The 'best-fit' linear regression line for the correlation between batch age and nicotinic acid content is indicated by a solid line; the dotted lines indicate the 95% confidence intervals for this line based on the available data.

possibility unlikely. It has been reported that methylnicotinate-induced erythema is reduced with age [19]. We did not observe, however, a statistically significant correlation between age and erythema (for example the Pearson correlation coefficient between erythema at 15 minutes and subject age was -0.31 ; $P < 0.05$), although the small sample size may have prevented us from detecting such a relationship.

Conclusion

Our data suggests that the degradation of methylnicotinate proceeds slowly in aqueous solution. Chromatographic analysis indicates that the methylester gradually hydrolyses at the rate of approximately 0.5% per annum to form nicotinic acid and, presumably, methanol. No other degradation products were noted. This rate of degradation had no apparent effect upon the ability of aged batches, prepared up to approximately 3 years prior, to induce erythema in healthy subjects. Since erythema was determined visually it remains a possibility that detection methods which are able to detect smaller changes in blood flow, such as laser Doppler spectroscopy, would have detected an effect of storage time. Such a possibility is unlikely, however, given that the extent of degradation in batches prepared 1062 days prior (approximately 1.5%) is rather lower than the test-retest variance of laser Doppler measurements which are in the range of 5 – 10%

(BMR, unpublished observations). It is important to note that the methylnicotinate solutions used in this study had a concentration of 1 M and had been stored refrigerated at 4°C in glass containers. It is possible that storage of solutions at different concentrations, or in containers made from substances other than glass would have given contrary results due to, for example, absorption to the surface of the container. Moreover, storage at higher temperatures e.g. room temperature would likely have resulted in higher rates of degradation, although it is common for test reagents to be stored in a refrigerator. Nevertheless, our overall conclusion is that methylnicotinate solutions can be stored for extended periods of time at 4°C in glass containers without the occurrence of extensive chemical degradation or loss of biological activity. This finding may aid the use of methylnicotinate for research purposes or for future clinical diagnostic uses.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

BMR carried out the chemical analysis and erythema study, while both BMR and MK analysed the data and wrote the manuscript. Both authors approved of the final version of the manuscript.




Figure 2
Analysis of methylnicotinate solutions by HPLC. Representative chromatograms are shown for (A) nicotinic acid standard, (B) 6-methyl nicotinate standard, (C) 6-methylnicotinate solution stored for 5 days at 4°C prior to analysis and (D) 6-methylnicotinate solution stored for 1062 days at 4°C prior to analysis.




Figure 3
Lack of effect of storage time upon extent of erythema induced by methylnicotinate. 10 mM aqueous solutions of methylnicotinate prepared from stock solutions which had been stored for various lengths of time at 4°C were applied to the forearm of 8 healthy volunteers and the induced erythema assessed visually at 5, 10 and 15 minutes post-application using a 4-point scale. Values shown are mean erythema; bars indicate the standard deviation.

Acknowledgements

This work was funded by a grant from the European Union Development Fund to BMR. The funding agency had no role in the design of the study or in the writing of the manuscript.

References

- Morrow JD, Parsons WG 3rd, Roberts LJ 2nd: **Release of markedly increased quantities of prostaglandin D₂ in vivo in humans following the administration of nicotinic acid.** *Prostaglandins* 1989, **38**:263-274.
- Morrow JD, Awad JA, Oates JA, Roberts LJ 2nd: **Identification of skin as a major site of prostaglandin D₂ release following oral administration of niacin in humans.** *J Invest Dermatol* 1992, **98**:812-815.
- Ward PE, Sutherland J, Glen EM, Glen AI: **Niacin skin flush in schizophrenia: a preliminary report.** *Schizophr Res* 1998, **29**:269-274.
- Caselli A, Hanane T, Jane B, Carter S, Khaodhiar L, Veves A: **Topical methyl nicotinate-induced skin vasodilation in diabetic neuropathy.** *J Diabetes Complications* 2003, **17**:205-210.
- Jumbelic LC, Liebel FT, Southall MD: **Establishing a minimal erythema concentration of methyl nicotinate for optimum evaluation of anti-inflammatories.** *Skin Pharmacol Physio* 2006, **19**:147-152.
- Puri BK, Singh I: **Normal phospholipid-related signal transduction in autism.** *Prog Neuropsychopharmacol Biol Psychiatry* 2002, **26**:1405-1407.
- Puri BK: **Impaired phospholipid-related signal transduction in advanced Huntington's disease.** *Exp Physiol* 2001, **86**:683-685.
- Katzman M, Cornacchi S, Coonerty-Femiano A, Hughes B, Vermani M, Struzik L, Ross BM: **Methyl nicotinate-induced vasodilation**

- in generalized social phobia. *Neuropsychopharmacology* 2003, **28**:1846-1851.
9. Ross BM, Ward P, Glen I: **Delayed vasodilatory response to methylnicotinate in patients with unipolar depressive disorder.** *J Affect Disord* 2004, **82**:285-290.
 10. Bosveld-van Haandel L, Knegtering R, Kluiters H, Bosch RJ van den: **Niacin skin flushing in schizophrenic and depressed patients and healthy controls.** *Psychiatry Res* 2006, **143**:303-306.
 11. Shah SH, Vankar GK, Peet M, Ramchand CN: **Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin.** *Schizophr Res* 2000, **43**:163-164.
 12. Puri BK, Easton T, Das I, Kidane L, Richardson AJ: **The niacin skin flush test in schizophrenia: a replication study.** *Int J Clin Pract* 2001, **55**(6):368-370.
 13. Messamore E, Hoffman WF, Janowsky A: **The niacin skin flush abnormality in schizophrenia: a quantitative dose-response study.** *Schizophr Res* 2003, **62**:251-258.
 14. Ross BM, Hughes B, Turenne S, Seeman M, Warsh JJ: **Reduced vasodilatory response to methylnicotinate in schizophrenia as assessed by laser Doppler flowmetry.** *Eur Neuropsychopharmacol* 2004, **14**:191-197.
 15. Smesny S, Rosburg T, Riemann S, Baur K, Rudolph N, Berger G, Sauer H: **Impaired niacin sensitivity in acute first-episode but not in multi-episode schizophrenia.** *Prostaglandins Leukot Essent Fatty Acids* 2005, **72**:393-402.
 16. Lin SH, Liu CM, Chang SS, Hwu HG, Liu SK, Hwang TJ, Hsieh MH, Guo SC, Chen WJ: **Familial aggregation in skin flush response to niacin patch among schizophrenic patients and their nonpsychotic relatives.** *Schizophr Bull* 2007, **33**:174-182.
 17. Liu CM, Chang SS, Liao SC, Hwang TJ, Shieh MH, Liu SK, Chen WJ, Hwu HG: **Absent response to niacin skin patch is specific to schizophrenia and independent of smoking.** *Psychiatry Res* 2007, **152**:181-187.
 18. Chang SS, Liu CM, Lin SH, Hwu HG, Hwang TJ, Liu SK, Hsieh MH, Guo SC, Chen WJ: **Impaired Flush Response to Niacin Skin Patch Among Schizophrenia Patients and Their Nonpsychotic Relatives: The Effect of Genetic Loading.** *Schizophr Bull* 2008 in press.
 19. Smesny S, Rosburg T, Klemm S, Riemann S, Baur K, Rudolph N, Grunwald S, Sauer H: **The influence of age and gender on niacin skin test results – implications for the use as a biochemical marker in schizophrenia.** *J Psychiatr Res* 2004, **38**:537-543.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

